Guadecitabine may be option for certain MDS/AML patients
March 12, 2019|Hematology and Oncology
REPORTING FROM HAEMATOLOGICA
There were 99 serious adverse events (AEs) reported in 44 patients. Most AEs were hematologic events, and the most common of these was myelosuppression (n = 88; 88%). The most common grade 3/4 nonhematologic AE was pulmonary toxicity (n = 7; 12.5%). Thirteen patients were hospitalized for febrile neutropenia for a median of 14 days.
The researchers said patients reported less pain and fewer secondary lesions with guadecitabine than they had with azacitidine.
This trial was sponsored by Groupe Francophone des Myelodysplasies in collaboration with Astex Pharmaceuticals. The researchers reported having no competing interests.
SOURCE: Sébert M et al. Haematologica. 2019 Feb 7. doi: 0.3324/haematol.2018.207118.
